UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 193

Sortiert nach

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Journal for immunotherapy of cancer, 2016-10, Vol.4 (1), p.60-60, Article 60

2016

Volltextzugriff (PDF)

Tandem Incorporation of Enantiomeric Residues Engenders Discrete Peptoid Structures

Organic letters, 2016-06, Vol.18 (11), p.2780-2783

2016

Volltextzugriff (PDF)

Synthesis of Functionalized Oxacalix[4]arenes

Organic letters, 2005-01, Vol.7 (1), p.91-94

2005

Volltextzugriff (PDF)

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Annals of oncology, 2015-11, Vol.26 (11), p.2267-2274

2015

Volltextzugriff (PDF)

Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma

Annals of oncology, 2011-04, Vol.22 (4), p.787-793

2011

Volltextzugriff (PDF)

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors

Annals of oncology, 2015-07, Vol.26 (7), p.1481-1487

2015

Volltextzugriff (PDF)

Synthesis of Oxacalixarenes Incorporating Nitrogen Heterocycles: Evidence for Thermodynamic Control

Organic letters, 2006-06, Vol.8 (13), p.2755-2758

2006

Volltextzugriff (PDF)

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

Annals of oncology, 2018-10, Vol.29, p.viii736-viii736

2018

Volltextzugriff (PDF)

Application of H/D Exchange to Hydrogen Bonding in Small Molecules

Chemistry : a European journal, 2013-11, Vol.19 (45), p.15101-15104

2013

Volltextzugriff (PDF)

Pathological complete response after neoadjuvant pembrolizumab and radiation

Clinical and experimental dermatology, 2019-07, Vol.44 (5), p.570-573

2019

Volltextzugriff (PDF)

Concomitant conformational dimorphism in 1,2-bis(9-anthryl)acetylene

CrystEngComm, 2015-01, Vol.17 (26), p.4877-4882

2015

Volltextzugriff (PDF)

Electronic Structure Studies of Oxomolybdenum Tetrathiolate Complexes: Origin of Reduction Potential Differences and Relationship to Cysteine−Molybdenum Bonding in Sulfite Oxidase

Inorganic chemistry, 2000-12, Vol.39 (25), p.5697-5706

2000

Volltextzugriff (PDF)

Characterization of a messenger RNA polynucleotide vaccine vector

Cancer research (Chicago, Ill.), 1995-04, Vol.55 (7), p.1397-1400

1995

Volltextzugriff (PDF)

Human Autoantibodies to Carcinoembryonic Antigen (CEA) Induced by a Vaccinia-CEA Vaccine

Clinical cancer research, 2000-01, Vol.6 (1), p.34-41

2000

Volltextzugriff (PDF)

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

The New England journal of medicine, 2011-06, Vol.364 (26), p.2507-2516

2011

Volltextzugriff (PDF)

LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)

Annals of oncology, 2022-09, Vol.33, p.S1406

2022

Volltextzugriff (PDF)

Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration

Clinical cancer research, 1999-09, Vol.5 (9), p.2330-2337

1999

Volltextzugriff (PDF)

Single-step synthesis of D3h-symmetric bicyclooxacalixarenes

Organic letters, 2005-08, Vol.7 (16), p.3505-3507

2005

Volltextzugriff (PDF)

Selected strategies to augment polynucleotide immunization

Gene therapy, 1996-01, Vol.3 (1), p.67

1996

Volltextzugriff (PDF)

Synthesis and Characterization of Square Planar Nickel(II)−Arylthiolate Complexes with the Biphenyl-2,2‘-dithiolate Ligand

Inorganic chemistry, 2000-04, Vol.39 (8), p.1674-1679

2000

Volltextzugriff (PDF)

Copper Complexes with N-Alkylated NS2-Macrocyclic Ligands: Synthesis, Characterization, and Capabilities as Aziridination Precatalysts

Organometallics, 2004-10, Vol.23 (22), p.5210-5218

2004

Volltextzugriff (PDF)

Immune response to a carcinoembryonic antigen polynucleotide vaccine

Cancer research (Chicago, Ill.), 1994-03, Vol.54 (5), p.1164-1168

1994

Volltextzugriff (PDF)

LBA66 - Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

Annals of oncology, 2019-10, Vol.30, p.v903-v903

2019

Volltextzugriff (PDF)

LBA66Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

Annals of oncology, 2019-10, Vol.30, p.v903

2019

Volltextzugriff (PDF)

1 – 25 von 193

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(169)

Publikationsform

Sprache

Englisch
(192)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

Tandem Incorporation of Enantiomeric Residues Engenders Discrete Peptoid Structures

Synthesis of Functionalized Oxacalix[4]arenes

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma

Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors

Synthesis of Oxacalixarenes Incorporating Nitrogen Heterocycles: Evidence for Thermodynamic Control

Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

Application of H/D Exchange to Hydrogen Bonding in Small Molecules

Pathological complete response after neoadjuvant pembrolizumab and radiation

Concomitant conformational dimorphism in 1,2-bis(9-anthryl)acetylene

Electronic Structure Studies of Oxomolybdenum Tetrathiolate Complexes: Origin of Reduction Potential Differences and Relationship to Cysteine−Molybdenum Bonding in Sulfite Oxidase

Characterization of a messenger RNA polynucleotide vaccine vector

Human Autoantibodies to Carcinoembryonic Antigen (CEA) Induced by a Vaccinia-CEA Vaccine

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

LBA39 Final 5-year results of the phase II, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL)

Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration

Single-step synthesis of D3h-symmetric bicyclooxacalixarenes

Selected strategies to augment polynucleotide immunization

Synthesis and Characterization of Square Planar Nickel(II)−Arylthiolate Complexes with the Biphenyl-2,2‘-dithiolate Ligand

Copper Complexes with N-Alkylated NS2-Macrocyclic Ligands: Synthesis, Characterization, and Capabilities as Aziridination Precatalysts

Immune response to a carcinoembryonic antigen polynucleotide vaccine

LBA66 - Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

LBA66Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma

Aktive Filter

Suchergebnisse filtern